Senesco Technologies to Present at the 11th Annual BIO CEO & Investor Conference

NEW BRUNSWICK, N.J., Feb. 5  /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US: SNT) today announced that the Company will be presenting at the 11th Annual BIO CEO & Investor Conference, which is being held at the Waldorf-Astoria Hotel in New York City from February 9th - 10th, 2009.  Bruce Galton, Chief Executive Officer of Senesco, will deliver the Company's corporate presentation on Monday, February 9th, at 9:30 AM ET.

The BIO CEO & Investor Conference is the largest investor conference focused on publicly traded biotech companies.  The conference provides a neutral forum where institutional investors, industry analysts and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.

The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.

About Senesco Technologies, Inc.

Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, N.J.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the successful conversion of the Company's letter of intent into a license agreement; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

  Company Contact:                    Investor Relations Contact:
  Senesco Technologies, Inc.          FD
  Bruce Galton                        Brian Ritchie
  Chief Executive Officer             ()
  ()               [phone]
  [phone]


DATASOURCE: Senesco Technologies, Inc.



CONTACT:  Company Contact, Bruce Galton, Chief Executive Officer, Senesco

Technologies, Inc., [phone], , or Investor

Relations Contact, Brian Ritchie, FD, [phone], 



Web Site:  http://www.senesco.com/ 

Copyright